Get in on Atea Pharmaceuticals Inc.’s (AVIR) buy-in window today!

Atea Pharmaceuticals Inc. (NASDAQ: AVIR) stock fell -2.43% on Wednesday to $4.81 against a previous-day closing price of $4.93. With 1.26 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.74 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.9800 whereas the lowest price it dropped to was $4.7750. The 52-week range on AVIR shows that it touched its highest point at $9.79 and its lowest point at $2.94 during that stretch. It currently has a 1-year price target of $4.00.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AVIR was up-trending over the past week, with a rise of 27.25%, but this was up by 46.20% over a month. Three-month performance surged to 24.29% while six-month performance rose 6.42%. A look at the trailing 12-month EPS for AVIR yields -1.31 with Next year EPS estimates of -2.84. For the next quarter, that number is -0.47. This implies an EPS growth rate of -201.40% for this year and -33.30% for next year.

Float and Shares Shorts:

At present, 83.33 million AVIR shares are outstanding with a float of 75.70 million shares on hand for trading. On Apr 27, 2023, short shares totaled 1.94 million, which was 2.33% higher than short shares on Mar 30, 2023. In addition to Dr. Jean-Pierre Sommadossi Ph.D. as the firm’s Founder, Chairman, CEO & Pres, Ms. Andrea J. Corcoran J.D. serves as its CFO, Exec. VP of Legal & Sec.

Institutional Ownership:

Through their ownership of 70.68% of AVIR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 37.23% of AVIR, in contrast to 28.12% held by mutual funds. Shares owned by individuals account for 23.64%. As the largest shareholder in AVIR with 13.89% of the stake, Fidelity Management & Research Co holds 11,573,379 shares worth 11,573,379. A second-largest stockholder of AVIR, BlackRock Fund Advisors, holds 6,382,395 shares, controlling over 7.66% of the firm’s shares. EcoR1 Capital, LLC is the third largest shareholder in AVIR, holding 6,184,861 shares or 7.42% stake. With a 3.51% stake in AVIR, the Fidelity Growth Company Fund is the largest stakeholder. A total of 2,921,924 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.70% of AVIR stock, is the second-largest Mutual Fund holder. It holds 2,253,893 shares valued at 7.37 million. Fidelity Series Growth Company Fu holds 2.02% of the stake in AVIR, owning 1,679,012 shares worth 5.49 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, AVIR reported revenue of $0.00 and operating income of -$32.30M. The EBITDA in the recently reported quarter was -$32.25M and diluted EPS was -$0.38.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AVIR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AVIR analysts setting a high price target of $8.00 and a low target of $4.00, the average target price over the next 12 months is $5.33. Based on these targets, AVIR could surge 66.32% to reach the target high and fall by -16.84% to reach the target low. Reaching the average price target will result in a growth of 10.81% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded AVIR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 0 while 41,666 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *